Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Argus Health
Deloitte
Citi
Johnson and Johnson
Daiichi Sankyo
Julphar
Covington
Accenture

Generated: December 17, 2018

DrugPatentWatch Database Preview

VIZAMYL Drug Profile

« Back to Dashboard

Which patents cover Vizamyl, and what generic alternatives are available?

Vizamyl is a drug marketed by Ge Healthcare and is included in one NDA. There are five patents protecting this drug.

This drug has seventy-six patent family members in twenty-three countries.

The generic ingredient in VIZAMYL is flutemetamol f-18. One supplier is listed for this compound. Additional details are available on the flutemetamol f-18 profile page.

Summary for VIZAMYL
Drug patent expirations by year for VIZAMYL
Generic Entry Opportunity Date for VIZAMYL
Generic Entry Date for VIZAMYL*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
INJECTABLE;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for VIZAMYL
Synonyms for VIZAMYL
((18 sup)F)AH110690
[18F]-Flutemetamol
[18F]-Flutemetamol F18
[18F]AH110690
[18F]flutemetamol
18F-Flutemetamol
2-(3-((18 sup)F)Fluoro-4-(methylamino)phenyl)-1,3-benzothiazol-6-ol
2-(3-(sup 18)f)Fluoro-4-(methylamino)phenyl)-1,3-benzothiazol-6-ol
2-[3-((18)F)fluoro-4-(methylamino)phenyl]-1,3-benzothiazol-6-ol
2-[3-(18F)fluoro-4-(methylamino)phenyl]-1,3-benzothiazol-6-ol
6-Benzothiazolol, 2-(3-(fluoro-(sup 18)F)-4-(methylamino)phenyl)-
765922-62-1
CHEBI:76611
CHEMBL2042122
D10231
DB09151
DTXSID80227394
Flutemetamol
flutemetamol ((18)F)
Flutemetamol ((sup 18)F)
Flutemetamol ((sup18)F)
flutemetamol (18F)
Flutemetamol (18F) [INN]
Flutemetamol F 18
Flutemetamol F 18 (USAN)
Flutemetamol F 18 [USAN]
flutemetamol F 18 injection
Flutemetamol F-18
Flutemetamol F18
GTPL7342
L49M066S0O
SCHEMBL10032147
UNII-L49M066S0O
Vizamyl (TN)

US Patents and Regulatory Information for VIZAMYL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-001 Oct 25, 2013 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-002 Oct 25, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-001 Oct 25, 2013 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-002 Oct 25, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for VIZAMYL

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
634 Luxembourg ➤ Try a Free Trial PRODUCT NAME: FLUTEMETAMOL (18F) ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (VIZAMYL). FIRST REGISTRATION: 20140826
90010-3 Sweden ➤ Try a Free Trial PRODUCT NAME: FLUTEMETAMOL (18F); REG. NO/DATE: EU/1/14/941 20140826
00723 Netherlands ➤ Try a Free Trial PRODUCT NAME: FLUTEMETAMOL (18 F); REGISTRATION NO/DATE: EU/1/14/941 20140822
15/005 Ireland ➤ Try a Free Trial PRODUCT NAME: VIZAMYL-FLUTEMETAMOL (18F); REGISTRATION NO/DATE: EU/1/14/941 20140822
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Argus Health
Deloitte
Citi
Johnson and Johnson
Daiichi Sankyo
Julphar
Covington
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.